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ABSTRACT
The CDC42 small GTPase is a major influence on actin-myosin cytoskeleton organization and
dynamics, signalling via effector proteins including the Myotonic dystrophy related CDC42-
binding protein kinases (MRCK) α and β. We previously identified Serine 1003 of MRCKα as
a site of autophosphorylation, and showed that a phosphorylation-sensitive antibody raised
against this site could be used as a surrogate indicator of kinase activity. In this study, a kinase-
dead version of MRCKβ was established by mutation of the conserved Lysine 105 to Methionine
(K105M), which was then used for mass spectrometry analysis to identify phosphorylation events
that occurred in catalytically-competent MRCKβ but not in the kinase-dead form. A total of ten
phosphorylations were identified on wild-type MRCKβ, of which the previously undescribed
Threonine 1108 (Thr1108) was not found on kinase-dead MRCKβ K105M, consistent with this
being due to autophosphorylation. Mutation of Thr1108 to non-phosphorylatable Alanine
(T1108A) or phosphomimetic Glutamate (T1108E) did not affect the ability of MRCKβ to phos-
phorylate recombinant myosin light chain in vitro, or observably alter the subcellular localization
of green fluorescent protein (GFP)-tagged MRCKβ expressed in MDA MB 231 human breast cancer
cells. Although phosphorylation of Thr1108 did not appear to contribute to MRCKβ function or
regulation, the identification of this phosphorylation does make it possible to characterize
whether this site could be used as a surrogate biomarker of kinase activity and inhibitor efficacy
as we previously demonstrated for Ser 1003 in MRCKα.
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Introduction
The actomyosin cytoskeleton is an interacting network
of polymerized actin filaments (F-actin) and multi-
molecular complexes of myosin heavy and light chains,
which provide the structure and physical force that
define cell shape and power morphological changes [1].
The forces generated by actomyosin contraction also
contribute to dynamic processes including motility, divi-
sion, and endocytosis at the cellular level, and muscle
contraction at the tissue level. Aberrant regulation of
actomyosin function may contribute to a range of
human diseases or pathological conditions including
cancer, hypertension and developmental disorders [2].
The small GTPase CDC42 plays essential roles in
actin-myosin cytoskeleton regulation and cell moti-
lity [3,4] through effector proteins including Myotonic
dystrophy related CDC42-binding protein kinases
(MRCK) α and β [5,6]. MRCKα and MRCKβ are ser-
ine/threonine kinases, and are part of the larger AGC
kinase family [7], including their next closest relatives
ROCK1 and ROCK2 [8]. Several studies have reported
that the MRCK and ROCK kinases act together to
promote cancer cell motility and invasion, consistent
with them having complementary roles in cytoskeleton
regulation [9,10]. The MRCKα and MRCKβ kinase
domains are approximately 85% identical and they
share a common set of substrates, including phosphor-
ylation of myosin II regulatory light chains (MLC) on
Serine 18(S18), which leads to myosin activation and
actin-myosin filament contraction. The discovery of
potent MRCK inhibitors has enabled the characteriza-
tion of the role of these kinases in cytoskeleton regula-
tion, morphology and motility [11,12], as well as in skin
cancer growth and glioma invasion [11,13].
Likely due to the close relatedness of the MRCK and
ROCK kinase domains, no substrates specific to an indi-
vidual kinase have been identified, with the exceptions of
MRCKα autophosphoryation on Ser1003, ROCK1 on
Ser1333 [14] and ROCK2 on Ser1366 [15]. Phospho-
sensitive antibodies raised against these sites revealed
that these autophosphorylation events were directly asso-
ciated with kinase activity, indicating that the phosphor-
ylation status of each residue can be used as a surrogate
biomarker of the corresponding kinase’s activation state.
Furthermore, immunohistochemical (IHC) analysis of
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breast cancer samples with the ROCK1 and ROCK2
autophosphorylation site antibodies revealed that nuclear
ROCK2 activation was associated with increased metas-
tasis and poor patient outcomes [16]. Similar IHC analy-
sis of mouse models of skin cancer and human glioma
specimens with an autophosphorylation-sensitive anti-
body indicated that increased MRCKα activity was asso-
ciated with tumourigenesis [11,13].
In order to identify MRCKβ autophosphorylations,
an approach similar to our previous study with MRCKα
was employed [11], in which phosphorylation sites
were identified by mass spectrometry (MS) that
occurred on catalytically competent but not kinase-
dead MRCKβ. In this study, we determined that active
MRCKβ becomes phosphorylated on Thr1108, which
does not occur on the kinase-dead protein. We inves-
tigated the function of this phosphorylation using
in vitro kinase assays and analysis of protein subcellular
by immunofluorescence microscopy.
Results
Expression of MRCKα and MRCKβ in human tissues
Given the high degree of homology and overlap in bio-
logical functions between the two MRCK proteins, we
wished to determine whether differences in the expres-
sion of the MRCKα (CDC42BPA, ENSG000
00143776.14) and MRCKβ (CDC42BPB, ENSG000
00198752.5) genes across human tissues might indicate
that one or the other had a more prominent role in
some contexts. Using the Broad Institute’s Genotype-
Tissue Expression (GTEx) project portal (gtexportal.
org/home/) examine tissue-specific gene expression
from 53 non-diseased sites across 714 individuals, the
patterns of MRCKα and MRCKβ expression were com-
parable across tissues (Figure 1(a,b)). However, the levels
of MRCKβ expression, measured as specific transcripts
per million (TPM) were higher than MRCKα in every
tissue (Figure 1(c)). Deming regression analysis revealed
that the slope of a fit line (2.98 ± 0.31) was significantly
(p < 0.0001) different from 0, indicating that MRCKβ
expression is approximately three-fold higher than
MRCKα across tissues in humans. Assuming that the
activity and function of the two MRCK proteins are
equivalent, these data indicate that MRCKβ likely
makes a relatively greater contribution than MRCKα in
healthy and diseased tissues.
Inactivation of MRCKβ by mutation of Lys105
Members of the AGC kinase family have a conserved
Lysine residue that is responsible for co-ordinating the α
and β phosphates of ATP, which is essential for cataly-
sis [17]. In MRCKα, Lys106 had previously been shown
to be necessary for activity and substrate phosphoryla-
tion [18], which we also found to be necessary for autopho-
sphorylation [11]. Our crystal structure of the MRCKβ
kinase domain (PDB 4UAK) [10] (Figure 2(a)) placed the
homologous Lys105 in close proximity to the ADP β phos-
phate (Figure 2(a) boxed region, Figure 2(b)). We mutated
the MRCKβ Lys105 to Methionine (MRCKβ K105M) and
investigated its ability to phosphorylate recombinant
gluthathione-S-transferase (GST)-MLC. When myc-
epitope tagged MRCKβ was immunoprecipitated (IP)
from transfected HEK293 cells and assayed in vitro for the
ability to phosphorylate GST-MLC on S18/T19 sites, the
robust phosphorylation observed with MRCKβ was absent
in the K105M mutant (Figure 3), indicating that Lys105 is
essential for MRCKβ kinase activity.
MRCKβ autophosphorylates on Thr1108
To identify MRCKβ autophosphorylation sites, mass spec-
trometry was used to identify amino acids modified by
phosphorylation in full length active MRCKβ and in full
length inactive MRCKβ-K105M. MRCKβ and MRCKβ-
K105M were expressed in HEK293 cells, immunoprecipi-
tated, and analyzed by mass spectrometry (Figure 4(a)).
The experiment was repeated 3 times in duplicates result-
ing in 6 samples per condition. Two related tryptic frag-
ments (amino acids 1104–1111 VPKP(pT)GVK and
1104–1112 VPKP(pT)GVKK) containing phosphorylated
Thr1108 were observed in all 6 samples from wild-type
MRCKβ but not from kinase-dead MRCKβ-K105M
(Figure 4(b)). A total of 10 phosphorylation sites were
identified (Table 1), of which 8 had been previously iden-
tified and are listed on the PhosphoSitePlus database
(Thr423, Ser481, Thr676, Ser868, Ser1680, Ser1686,
Ser1690 and Ser1693). Two sites were not previously
identified (Thr1108 and Ser1683). An example MS/MS
spectra of a human MRCKβ peptide (1104–1111
VPKPTGVK) containing phosphorylated Thr1108 is
shown in Figure 4(c). The crystal structure of the
MRCKβ kinase domain revealed that phosphorylation
was not essential for an active conformation to be
adopted, and consistent with this observation there were
no phosphorylations detected in the amino-terminal
kinase region. By inference, the previously unidentified
Thr1108 phosphorylation is an autophosphorylation
event since it was observed in active MRCKβ but not
kinase-dead MRCKβ-K105M. Alignment of the regions
adjacent to the previously identified MRCKα autopho-
sphorylations (Ser1003 and Thr1012) [11] and the
MRCKβ Thr1108 autophosphorylation revealed that
none of these residues is conserved (Figure 4(d)).
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Figure 1. Gene expression of MRCKα and MRCKβ in human tissues. (a) The expression of MRCKα (Ensembl ENSG00000143776.14)
and (b) MRCKβ (Ensembl ENSG00000198752.5) were deteremined by The Genotype-Tissue Expression (GTEx) project from 53 non-
diseased tissue sites across 714 individuals (release v7). Expression values are shown in transcripts per million (TPM) in which
possible isoforms were collapsed to a single gene. Box plots indicate upper and lower quartiles, outliers are ± 1.5 times the
interquartile range. (c) Median gene expression values for MRCKα and MRCKβ were plotted to indicate their relative expression in
each tissue. Dotted line has a slope = 1, points above it are expressed at relatively higher levels in MRCKβ relative to MRCKα.
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Thr1108 phosphorylation does not regulate MRCKβ
activity
Previously published analysis of MRCKα regulation sug-
gested that an internal region containing two coiled-coil
domains (amino acids 658 to 930) negatively regulated
kinase activity [18], raising the possibility that similarly
positioned phosphorylations might regulate activity.
Having identified Thr1108 as a putative MRCKβ autop-
hosphorylation, we investigated the role of this phosphor-
ylation on kinase activity towards a substrate protein by
changing Thr1108 to a non-phosphorylatable Alanine
(T1108A) or to phosphomimetic Glutamic acid
(T1108E). As previously observed, wild-type MRCKβ
robustly phosphorylated recombinant GST-MLC and
MRCKβ K105M did not, while both MRCKβ T1108A
and MRCKβ T1108E phosphorylated substrate to
a comparable extent (Figure 5(a,b)). These observations
indicate that phosphorylation of Thr1108 is not required
for activity, nor does it negatively affect substrate
phosphorylation.
Lys105 ADP
MRCK ba
Figure 2. Position of MRCKβ Lys105. (a) The crystal structure of the kinase domain of MRCKβ in complex with ADP (PDB 4UAK) [10]
was rendered with UCSF Chimera [28] to show the position of the Lys105 side chain relative to the ADP phosphates (boxed region).
(b) The boxed region is shown at higher magnification to show the close proximity of the Lys105 side chain relative to the ADP
phosphates.
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Figure 3. MRCKβ Lys105 is essential for kinase activity. (a) Western blot of immunoprecipitated myc-tagged MRCKβ and MRCKβ-
K105M (green) that were placed in kinase buffer along recombinant GST-MLC (green). Probing with an antibody against the doubly
phosphorylated Ser18/Thr19 MLC (pMLC, red) revealed that active MRCKβ phosphorylated MLC while no signal could be detected for
full length MRCKβ K105M. The molecular weights (MW) of proteins in a MW ladder (red) are indicated in kDa. Immunoglobulin (IgG)
from the immunoprecipitating antibody is revealed in red. (b) Individual panels of the immunoreactivity of immunoprecipitated (IP)
myc-tagged MRCKβ proteins (green), and proteins in the in vitro kinase assay: GST-MLC (green), pMLC (red), MLC/pMLC overlay.
4 M. UNBEKANDT ET AL.
Thr1108 phosphorylation does not regulate
subcellular localization
MRCKα and MRCKβ have been reported to be typically
cytoplasmic, with a proportion being translocated to,
or concentrated at, the plasma membrane upon activa-
tion [19,20]. To investigate the potential role of Thr1108
phosphorylation on MRCKβ cellular localization, we used
fluorescence microscopy to examine the distribution of
wild-type MRCKβ with a carboxy-terminal green
a b
c
d
Figure 4. Identification of MRCKβ phosphorylations. (a) SDS-PAGE gels of immunoprecipitated MRCKβ and MRCKβ-K105M in
duplicate were stained with Coomassie. Immunoprecipitations and subsequent mass spectrometry were performed in triplicate,
giving a total of 6 separate replicates. (b) Mascot scores of the 6 replicates samples for the two overlapping peptides indicated that
contain Thr1108 (red) from wild-type MRCKβ and kinase-dead MRCKβ K105M. (c) Positive ion MS/MS spectra and theoretical masses
of b (red) and y (blue) fragmentation series of the MRCKβ peptide VPKPTGVK (1104–1111) containing phosphorylated Thr1108 (red),
with the mass/charge peaks corresponding to Thr1108 indicated with boxes. (d) Alignment of the MRCKα and MRCKβ regions
containing the autophosphorylation sites identified in each protein [11].
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fluorescent protein tag (MRCKβ-GFP), and of kinase-
dead MRCKβ-GFP K105M, non-phosphorylatable
MRCKβ-GFP T1008A and phosphomimetic MRCKβ-
GFP T1008E in transfected MDA-MB-231 D3H2LN
human breast cancer cells [21]. No obvious differences
in MRCKβ distribution were observed when the Thr1108
phosphorylation site was mutated to Alanine or to
Glutamic acid, indicating that this site does not have
a major role in determining MRCKβ subcellular localiza-
tion (Figure 6).
Discussion
In this report, we determined that the MRCKβ Lys105 in
the ATP binding pocket (Figure 2) is essential for kinase
activity, mutation of Lysine to Methionine resulted in
the protein being catalytically inactive (Figure 3), similar
to previous observations on the essential role of Lys106
in MRCKα [11] of the protein and that mutation of this
amino acid renders the kinase dead.
By comparing the patterns of phosphorylation between
wild-type and kinase-dead MRCKβ, we identified 9 com-
mon phosphorylations and 1 that uniquely occurred in
wild-type but not kinase-dead MRCKβ (Figure 4), consis-
tent with this being an autophosphorylation event. By
mutating Thr1108 to a non-phosphorylatable Alanine
(T1108A) or phosphomimetic Glutamic Acid (T1108E),
Table 1. MRCKβ phosphorylation sites. MRCKβ phosphorylation
sites identified by Mascot from Orbitrap data acquired in linear
ion trap (CID in multistage activation) and/or higher energy
collision dissociation (HCD). Peptide start-phosphorylation site-
end positions are indicated for each peptide, with inferred
autophosphorylation site in red. The reported Mascot ion
score for an MS/MS match is −10Log(P) of the calculated
probability P that a match between experimental data and
database sequence is a random event. ND = not determined.
Peptide Sequence
(Phosphorylation or
Autophosphorylation
Underlined)
Start-Phosphorylation-
Stop Positions
(Autophosphorylation)
MRCKβ
Mascot
Score
(Mean,
n = 6)
MRCKβ
K105M
Mascot
Score
(Mean,
n = 6)
SIMQSNtLTKDEDVQR 417-T423-432 34.6 26.7
ALSNsNRDKEIK 477-S481-488 36.4 30.3
GAGAtLEHQQEISK 672-T676-685 68.9 68.3
sQKLDMSAR 868-S868-876 34.1 29.6
VPKPtGVK 1104-T1108-1111 30.6 ND
VPKPtGVKK 1104-T1108-1112 46.0 ND
HSTPsNSSNPSGPPSPNSPHR 1676-S1680-1696 ND 35.9
HSTPSNSsNPSGPPSPNSPHR 1676-S1683-1696 ND 41.5
HSTPSNSSNPsGPPSPNSPHR 1676-S1686-1696 44.7 42.7
HSTPSNSSNPSGPPsPNSPHR 1676-S1690-1696 113.2 112.9
HSTPSNSSNPSGPPSPNsPHR 1676-S1693-1696 90.0 88.3
HSTPSNSSNPsGPPsPNSPHR 1676-S1686-S1690-
1696
61.1 54.4
HSTPSNSSNPSGPPsPNsPHR 1676-S1690-S1693-
1696
61.4 41.1
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Figure 5. Thr1108 phosphorylation is not required for substrate phosphorylation. (a) Western blot of immunoprecipitated myc-
tagged MRCKβ, MRCKβ-K105M, MRCKβ-T1108A and MRCKβ-T1108E (red) that were placed in kinase buffer along recombinant GST-
MLC (green). Probing with pMLC antibody (red) revealed that active MRCKβ, MRCKβ-T1108A and MRCKβ-T1108E all comparably
phosphorylated MLC while no signal could be detected for kinase-dead MRCKβ K105M. MW ladder wieghts (red) indicated in kDa.
IgG from the immunoprecipitating antibody in red. (b) Individual panels of the immunoreactivity of immunoprecipitated (IP) myc-
tagged MRCKβ proteins (red), and proteins in the in vitro kinase assay: GST-MLC (green), pMLC (red), MLC/pMLC overlay.
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we determined that phosphorylation of this site is not
required for kinase activity (Figure 5), nor does it contribute
substantially to determining MRCKβ subcellular localiza-
tion (Figure 6). This phosphorylation has not been pre-
viously identified in studies curated in the PhosphoSitePlus
database.
We previously showed that the autophosphorylation
of MRCKα on Ser1003 could be used as a surrogate
indicator of kinase activity. An antibody against the
phosphorylated MRCKα Ser1003 revealed elevated levels
of active kinase in genetic and chemically-induced
mouse skin tumours, and also provided evidence that
topical application of a selective MRCK small molecule
inhibitor successfully blocked kinase activity [11]. We
attempted to raise a similar rabbit polyclonal phospho-
specific antibody against the MRCKβ Thr1108 site using
the peptide VPKP(pT)GVKKGWQRAC. The resulting
antibody showed phospho-specificity when assayed by
ELISA using immobilized phosphorylated and unpho-
sphorylated peptides (data not shown), but the antibody
did not perform adequately well for Western blotting of
cell lysates or for immunohistochemistry (data not
shown). By reporting the putative MRCKβ Thr1008
autophosphorylation, we hope this will encourage others
to attempt to develop such an antibody, which would be
useful to investigate MRCKβ biology and development
of MRCK inhibitors. Given that MRCKβ expression is
higher than MRCKα in every tissue examined (Figure 1),
it could be argued that the means to determine the level
of MRCKβ activity in diseases conditions or following
inhibitor treatment would be more informative than the
S1003 phosphorylation-sensitive antibody that we were
previously able to successfully generate and validate [11].
Materials and methods
Plasmids
The original source for the MRCKβ plasmids was the
pEGFP-N1-Cdc42BPB plasmid deposited by Naoki
Mochizuki in Addgene (#50759) [22]. pEGFP-N1-
MRCKβ-K105M was generated by site directed muta-
genesis of wild-type pEGFP-N1-MRCKβ using the
Quickchange II XL kit (Agilent Technologies) accord-
ing to manufacturer’s recommendations using the fol-
lowing primers:
K105M forward: 5ʹ-atactgaacgaatttatgcaatgatgatcct
caacaagtgggagatgc-3ʹ
K105M reverse: 5ʹ-gcatctcccacttgttgaggatcatcattgca
taaattcgttcagtat-3ʹ
The pcDNA-Myc-MRCKβ and pcDNA-Myc-MRCK
β-K105M plasmids were generated by inserting
MRCKβ sequences from pEGFP-N1-MRCKβ and
pEGFP-N1-MRCKβ-K105M into a pcDNA-myc con-
struct using restriction enzymes Kpn1 and BamH1.
The pEGFP-N1-MRCKβ-T1108A, pEGFP-N1-
MRCKβ-T1108E, pcDNA-Myc-MRCKβ-T1108A and
pcDNA-Myc-MRCKβ-T1108E plasmids were gener-
ated using the Q5 sited directed mutagenesis kit (New
England Biolabs) from pcDNA-Myc-MRCKβ using the
following primers:
T1108A forward: 5ʹ-CCCAAAGCCCGCGGGGGTG
AAGA-3ʹ
T1108A reverse: 5ʹ-ACCTTGACATGGCCTTTGT
AGGCTG-3ʹ
T1108E forward: 5ʹ-CCCAAAGCCCGAGGGGG
TGAAGA-3ʹ
T1108E reverse: 5ʹ-ACCTTGACATGGCCTTTG-3ʹ
MRCK -GFPβ
MRCK -GFP
K105M
β MRCK -GFP
T1108A
β MRCK -GFP
T1108E
β
MRCK Phalloidin DAPI
Figure 6. Subcellular localization of GFP-tagged MRCKβ is not affected by mutation of Thr1108. Confocal microscope images of
MDA-MB-231 D3H2LN cells expressing MRCKβ-GFP, MRCKβ-GFP K105M, MRCKβ-GFP T1108A or MRCKβ-GFP T1108E (green). Samples
were stained with Texas-Red conjugated phalloidin (red) to visualize filamentous actin and DAPI (blue) to localize nuclei. Scale bar
corresponds to 10 µm.
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MLC protein production
E. coli BL21 bacteria were transformed with pGEX2T-
MLC and grown on ampicillin plates (50 µg/mL).
A single colony was picked and cultured overnight at
37°C in 100mL of LB broth supplemented with ampicillin
(100 µg/mL). The culture was diluted 1 in 10 (30 mL into
300 mL of LB broth + ampicillin) and cultured for 1 hour
at 37°C. IPTG was applied at 50 µM for 3 hours, then
cultures were centrifuged at 4000 rpm for 15minutes at 4°
C, and the pellet was lysed in TBS +5 mMMgCl2 + 1 mM
DTT +1 mM PMSF. The lysates were sonicated 3 times
for 1minute on ice and then centrifuged at 10,000 rpm for
10 minutes at 4°C. The supernatant was collected and
used for in vitro MLC phosphorylation assays.
HEK293 cell culture, transfection and
immunoprecipitation
HEK293 cells were routinely cultured in DMEM+ 10%
FCS + L-glutamine at 37°C. 1 × 106 HEK293 cells were
plated per 10 cm culture plate, then the following day
mediumwas replaced with OPTIMEM. After 1 hour, cells
were transfected in OPTIMEM with 10 μg of pcDNA-
Myc-MRCKβ, pcDNA-Myc-MRCKβ-K105M, pcDNA-
Myc-MRCKβ-T1108A or pcDNA-Myc-MRCKβ-T1108E
as indicated using Fugene HD (Promega). After 6 hours,
medium was replaced with DMEM 10%FCS +
L-glutamine. Two days after transfection, cells were
placed on ice, washed in ice cold PBS and lysed in 1 mL
of ice cold lysis buffer (TBS + 1 mM EDTA + 1% Triton-
X100 + 1 mM PMSF + 1X cOmplete Protease inhibitor
(Roche) + 20 mM NaF + 20 mM β-glycophosphate +
0.2μM Na3VO4 + 20 μg/mL Aprotinin). Lysates were
incubated on a rotating wheel for 30 minutes at 4°C
before centrifugation at 13,200 rpm for 10 minutes at 4°
C, then supernatants were collected. Lysates were incu-
bated with anti-Myc agarose beads (Sigma, A7470) on
a rotating wheel for 2 hours at 4°C. The beads were then
washed 3 times in lysis buffer by successive centrifuga-
tions at 3000 rpm for 1 minute at 4°C. For mass spectro-
metry and western blots, beads were boiled at 95°C in 1%
SDS for 5 minutes, centrifuged at 3000 rpm for 2 minutes
and supernatants collected.
Western blots
Cell lysates and immunoblot analysis were performed as
described in [12]. The following antibodies were used:
rabbit anti-pMLC2 Thr18/Ser19 (Cell Signaling
Technology, 3674), MRCL3/MRLC2/MYL9 (Santa Cruz
Biotechnology, sc-28329), anti-DMPK (MANDMN1)
[23,24], and mouse anti-Myc tag (Cell Signaling
Technology, #2276).
MLC assays
For in vitro MLC phosphorylation assays, MRCKβ pro-
tein bound to anti-Myc beads after immunoprecipitation
were re-suspended in 95 μL of kinase buffer (20 mM
Tris HCl pH 7.4, 0.5 mM MgCl2, 0.01% Tween 20 and
1 mM DTT) with 2 μL of 5 mM ATP and 3 μL of
recombinant GST-MLC and incubated with constant
agitation at 30°C for 1 hour. To stop the reaction,
100 μL of boiling 2% SDS was added to the samples
and the reactions were incubated for 5 minutes at 95°C.
The samples were centrifuged at 3000 rpm for 2 minutes
and supernatants were collected for western blots.
Mass spectrometry
Full length MRCKβ and full length MRCKβ-K105M
were expressed in HEK293 cells and immunoprecipi-
tated as described above. Samples were run on SDS-
PAGE, and stained using InstantBlue Coomassie protein
stain (Expedeon). The bands containing MRCKβ were
excised and digested with trypsin according to
a previously described procedure [25]. The tryptic
digests obtained were separated by nanoscale C18
reverse-phase liquid chromatography using an EASY-
nLC II (Thermo Fisher Scientific) coupled to a Linear
Trap Quadrupole (LTQ) Orbitrap Velos mass spectro-
meter (Thermo Fisher Scientific). The eluted peptides
were injected into the mass spectrometer via
a nanoelectrospray ion source (Sonation). The mass
spectrometer was operated in positive ion mode and
used in data-dependent acquisition. Fragmentation was
performed on the top ten most intense ions using both
available fragmentation modes: collision energy dissocia-
tion (CID, using a multistage activation option) and
higher energy collision dissociation (HCD) in two sepa-
rated acquisitions.
Raw data obtained were processed with MaxQuant
version 1.5.5.1 [26]. Andromeda peak list files (.apl)
generated were converted to Mascot generic files (.
mgf) using APL to MGF Converter (wehi.edu.au/peo-
ple/andrew-webb/1298/apl-mgf-converter). MGF files
were searched using Mascot (Matrix Science, version
2.4.1), querying the UniProt [27] Homo sapiens data-
base (09/07/2016; 92,939 entries), plus an in-house
database containing common proteomic contaminants
and the sequence of kinase-dead MRCKβ. Mascot was
searched assuming the digestion enzyme trypsin allow-
ing for two miscleavages with a fragment ion mass
tolerance of 0.1 Da and a parent ion mass tolerance of
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15 ppm. The iodoacetamide derivative of cysteine was
specified in Mascot as a fixed modification. Oxidation
of methionine and phosphorylation of serine, threonine
and tyrosine were specified in Mascot as variable mod-
ifications. The MS/MS data of phosphopeptides were
manually curated with Xcalibur Qual Browser version
2.2 (Thermo Scientific), and the MS-Product utility of
Protein Prospector v5.12.4 (prospector.ucsf.edu/) was
used to generate theoretical product ions fragmentation
series.
Raw data, msms.txt files from MaxQuant and
Mascot DAT files were imported into Skyline to build
a library of MRCKβ peptides. Extracted ions chroma-
tograms (XICs) of the 3 main isotopic peaks (30 K
resolution at 400 m/z) of precursor ions from unmodi-
fied and phosphorylated peptides of MRCKβ that car-
ried 2+ and 3+ charges were used for quantification of
autophosphorylation sites.
MDA-MB-231 D3H2LN cell culture, transfection and
immunofluorescence
MDA-MB-231 D3H2LN cells were cultured in
DMEM + 10% FCS + L-glutamine. Cells were plated
at 105 cells per well of a 6 well plate, then the
following day medium was replaced with
OPTIMEM. After 1 hour, cells were transfected in
OPTIMEM with 3.3 μg of pEGFP-N1-MRCKβ,
pEGFP-N1-MRCKβ-T1108A or pEGFP-N1-MRCK
β-T1108E as indicated using Fugene HD
(Promega). After 6 hours, medium was replaced
with DMEM + 10% FCS + L-glutamine. Two days
after transfection, cells were washed in PBS and
fixed in 4% paraformaldehyde for 15 minutes. Cells
were washed twice in PBS, permeabilized for 15 min-
utes in 0.5% Triton X-100 in PBS, washed twice in
PBS and incubated for 1 hour in 1% BSA in PBS.
Cells were incubated for 1 hour at room temperature
with Texas-red conjugated phalloidin (Molecular
Probes, Invitrogen). Cells were washed and cover-
slips were mounted using Vectashield mounting
medium containing DAPI.
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